Data as of Apr 16
| +0.14 / +6.31%|
The 3 analysts offering 12-month price forecasts for KaloBios Pharmaceuticals Inc have a median target of 8.00, with a high estimate of 11.00 and a low estimate of 7.00. The median estimate represents a +238.98% increase from the last price of 2.36.
The current consensus among 4 polled investment analysts is to Buy stock in KaloBios Pharmaceuticals Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.